Cancer Drug

<p>A class in a securities fraud dispute plausibly pleaded that some of cancer drug company NewLink’s statements about scientific literature and the design of their clinical trial may have amounted to material misrepresentations, the Second Circuit <a href="https://www.courthousenews.com/wp-content/uploads/2020/07/cancerdrugsecurities.pdf"><strong>ruled</strong></a>.</p>

MANHATTAN — A class in a securities fraud dispute plausibly pleaded that some of cancer drug company NewLink’s statements about scientific literature and the design of their clinical trial may have amounted to material misrepresentations, the Second Circuit ruled .

Categories / Appeals, Business, Health, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.